Melanoma: New insights and new therapies

142Citations
Citations of this article
139Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metastatic melanoma has historically been considered as one of the most therapeutically challenging malignancies. However, for the first time after decades of basic research and clinical investigation, new drugs have produced major clinical responses. The discovery of BRAF mutations in melanoma created the first opportunity to develop oncogene-directed therapy in this disease and led to the development of compounds that inhibit aberrant BRAF activity. A decade later, vemurafenib, an orally available and well-tolerated selective BRAF inhibitor, ushered in a new era of molecular treatments for advanced disease. Additional targets have been identified, and novel agents that impact on various signaling pathways or modulate the immune system hold the promise of a whole new therapeutic landscape for patients with metastatic melanoma. One of the major thrusts in melanoma therapy is now focused on understanding and targeting the network of signal transduction pathways and on attacking elements that underlie the tumor's propensity for growth and chemoresistance. In this article, we review the novel targeted anticancer approaches that are under consideration in melanoma treatment. © 2012 The Society for Investigative Dermatology.

Cite

CITATION STYLE

APA

Nikolaou, V. A., Stratigos, A. J., Flaherty, K. T., & Tsao, H. (2012). Melanoma: New insights and new therapies. Journal of Investigative Dermatology. Nature Publishing Group. https://doi.org/10.1038/jid.2011.421

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free